Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 123 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Pemetrexed
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific, Veno-occlusive Disease
Interventions
Fragmin, placebo
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
2
States / cities
Rochester, Minnesota • Madison, Wisconsin
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Cholestyramine, Leflunomide
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Duarte, California • Detroit, Michigan • New York, New York + 1 more
Conditions
Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease, Light Chain Deposition Disease, Heavy Chain Deposition Disease, Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes, Smoldering Multiple Myeloma, Plasma Cell Leukemia
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Timeline
2018 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia of Lymph Nodes, Waldenstrom's Macroglobulinaemia, Without Mention of Remission, Waldenstrom's Macroglobulinemia Refractory
Interventions
Ibrutinib, Daratumumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Interventions
defined green tea catechin extract, gene expression analysis, protein analysis, laboratory biomarker analysis
Dietary Supplement · Genetic · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cilengitide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Light Chain Deposition Disease, Smoldering Multiple Myeloma
Interventions
Clinical Observation, Lenalidomide, Quality-of-Life Assessment
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
602
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 391 more
Conditions
Multiple Myeloma
Interventions
daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
15
States / cities
Little Rock, Arkansas • Jacksonville, Florida • West Palm Beach, Florida + 12 more
Conditions
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions
Relaxation Response Resiliency Program (3RP)
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Monoclonal Gammopathy of Undetermined Significance, Plasma Cell Myeloma
Interventions
5-Carbon C 13-labeled Glutamine, Biospecimen Collection, Uniformly-labeled [13C]glucose
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Interventions
Melphalan, Bortezomib, Dexamethasone, Autologous Transplant
Drug · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Completed No phase listed Observational

Comprehensive Frailty Assessment

NCT02033928
Conditions
Myeloma, Multiple, Paraproteinemias, Hematologic Neoplasms
Interventions
Not listed
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Refractory Multiple Myeloma, Smoldering Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
total marrow irradiation, melphalan, peripheral blood stem cell transplantation, filgrastim, fluorescence in situ hybridization, cytogenetic analysis, cyclophosphamide, autologous-autologous tandem hematopoietic stem cell transplantation, lenalidomide
Radiation · Drug · Procedure + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Duarte, California
Conditions
Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Interventions
beta alethine
Drug
Lead sponsor
LifeTime Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
Atlanta, Georgia • Rockville, Maryland • New York, New York
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Dexamethasone, Iberdomide Hydrochloride, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Spartanburg, South Carolina • Houston, Texas
Completed Phase 2 Interventional Results available

Imaging in MGUS, SMM and MM

NCT01237054
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
18-NaF PET, DCE-MRI, 18-FDG PET/CT
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
St. John's wort
Dietary Supplement
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Psychosocial Effects of Cancer and Its Treatment
Interventions
music therapy
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Smoldering Multiple Myeloma
Interventions
Selinexor
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rochester, New York
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions
therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida